Literature DB >> 12959926

Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats.

Tetsutaro Nagaoka1, Yoshiteru Morio, Nina Casanova, Natalie Bauer, Sarah Gebb, Ivan McMurtry, Masahiko Oka.   

Abstract

Recent evidence suggests that Rho/Rho kinase signaling plays an important role in the sustained vasoconstriction induced by many agonists and is involved in the pathogenesis of systemic vascular diseases. However, little is known about its role in increased vascular tone in hypoxic pulmonary hypertension (PH). The purpose of this study was to examine whether Rho/Rho kinase-mediated Ca2+ sensitization contributed to sustained vasoconstriction and increased vasoreactivity in hypoxic PH in rats. Acute intravenous administration of Y-27632, a Rho kinase inhibitor, nearly normalized the high pulmonary arterial blood pressure and total pulmonary resistance in chronically hypoxic rats. In contrast to nifedipine, Y-27632 also markedly decreased elevated basal vascular tone in hypertensive blood-perfused lungs and isolated pulmonary arteries. Y-27632 and another Rho kinase inhibitor, HA-1077, completely reversed nitro-L-arginine-induced vasoconstriction in physiological salt solution-perfused hypertensive lungs, whereas inhibitors of myosin light chain kinase (ML-9), protein kinase C (GF-109203X), phosphatidylinositol 3-kinase (LY-294002), and tyrosine kinase (tyrphostin A23) caused only partial or no reversal of the vasoconstriction. Vasoconstrictor responses to KCl were augmented in hypertensive physiological salt solution-perfused lungs and pulmonary arteries, and the augmentation was eliminated by Y-27632. These results suggest that Rho/Rho kinase-mediated Ca2+ sensitization plays a central role in mediating sustained vasoconstriction and increased vasoreactivity in hypoxic PH.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12959926     DOI: 10.1152/ajplung.00050.2003

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  80 in total

1.  Effects of acute Rho kinase inhibition on chronic hypoxia-induced changes in proximal and distal pulmonary arterial structure and function.

Authors:  Rebecca R Vanderpool; Ah Ram Kim; Robert Molthen; Naomi C Chesler
Journal:  J Appl Physiol (1985)       Date:  2010-11-18

2.  Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia.

Authors:  Yi Jin; Thomas J Calvert; Bernadette Chen; Louis G Chicoine; Mandar Joshi; John Anthony Bauer; Yusen Liu; Leif D Nelin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-02-19       Impact factor: 4.733

Review 3.  HIF and pulmonary vascular responses to hypoxia.

Authors:  Larissa A Shimoda; Steven S Laurie
Journal:  J Appl Physiol (1985)       Date:  2013-12-12

4.  Connectivity map analysis of nonsense-mediated decay-positive BMPR2-related hereditary pulmonary arterial hypertension provides insights into disease penetrance.

Authors:  Charles Flynn; Siyuan Zheng; Ling Yan; Lora Hedges; Bethany Womack; Josh Fessel; Joy Cogan; Eric Austin; James Loyd; James West; Zhongming Zhao; Rizwan Hamid
Journal:  Am J Respir Cell Mol Biol       Date:  2012-02-03       Impact factor: 6.914

5.  Patchy deletion of Bmpr1a potentiates proximal pulmonary artery remodeling in mice exposed to chronic hypoxia.

Authors:  Rebecca R Vanderpool; Nesrine El-Bizri; Marlene Rabinovitch; Naomi C Chesler
Journal:  Biomech Model Mechanobiol       Date:  2013-01

Review 6.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

7.  Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease.

Authors:  Fuhai Li; Wei Xia; Shuanghu Yuan; Ruopeng Sun
Journal:  Pediatr Cardiol       Date:  2008-10-25       Impact factor: 1.655

8.  Treating pulmonary arterial hypertension: current treatments and future prospects.

Authors:  Shahzad G Raja; Shahbaz M Raja
Journal:  Ther Adv Chronic Dis       Date:  2011-11       Impact factor: 5.091

Review 9.  Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: new findings for an old problem.

Authors:  Jeremy P T Ward; Ivan F McMurtry
Journal:  Curr Opin Pharmacol       Date:  2009-03-16       Impact factor: 5.547

Review 10.  Pathogenic mechanisms of pulmonary arterial hypertension.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  J Mol Cell Cardiol       Date:  2007-09-20       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.